WallStSmart

Abbott Laboratories (ABT)vsEstablishment Labs Holdings Inc (ESTA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 18851% more annual revenue ($46.59B vs $245.82M). ABT leads profitability with a 11.7% profit margin vs -15.8%. ABT earns a higher WallStSmart Score of 54/100 (C-).

ABT

Buy

54

out of 100

Grade: C-

Growth: 4.0Profit: 6.0Value: 3.3Quality: 6.0
Piotroski: 4/9Altman Z: 2.71

ESTA

Avoid

30

out of 100

Grade: F

Growth: 6.7Profit: 2.0Value: 4.7Quality: 5.0
Piotroski: 4/9Altman Z: -1.05
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-37.5%)

Margin of Safety

-37.5%

Fair Value

$74.13

Current Price

$101.95

$27.82 premium

UndervaluedFair: $74.13Overvalued
ESTAOvervalued (-11.7%)

Margin of Safety

-11.7%

Fair Value

$65.12

Current Price

$70.94

$5.82 premium

UndervaluedFair: $65.12Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT2 strengths · Avg: 8.5/10
Market CapQuality
$176.41B9/10

Large-cap with strong market position

Free Cash FlowQuality
$2.09B8/10

Generating 2.1B in free cash flow

ESTA1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
31.7%10/10

Revenue surging 31.7% year-over-year

Areas to Watch

ABT3 concerns · Avg: 3.3/10
PEG RatioValuation
1.904/10

Expensive relative to growth rate

P/E RatioValuation
33.4x4/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-47.5%2/10

Earnings declined 47.5%

ESTA4 concerns · Avg: 2.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
97.2x2/10

Trading at 97.2x book value

Return on EquityProfitability
-295.9%2/10

ROE of -295.9% — below average capital efficiency

Free Cash FlowQuality
$-20.15M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Free Cash Flow. Revenue growth of 13.0% demonstrates continued momentum.

Bull Case : ESTA

The strongest argument for ESTA centers on Revenue Growth. Revenue growth of 31.7% demonstrates continued momentum.

Bear Case : ABT

The primary concerns for ABT are PEG Ratio, P/E Ratio, EPS Growth.

Bear Case : ESTA

The primary concerns for ESTA are EPS Growth, Price/Book, Return on Equity. Debt-to-equity of 12.20 is elevated, increasing financial risk.

Key Dynamics to Monitor

ABT profiles as a value stock while ESTA is a hypergrowth play — different risk/reward profiles.

ESTA carries more volatility with a beta of 1.05 — expect wider price swings.

ESTA is growing revenue faster at 31.7% — sustainability is the question.

ABT generates stronger free cash flow (2.1B), providing more financial flexibility.

Bottom Line

ABT scores higher overall (54/100 vs 30/100) and 13.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Establishment Labs Holdings Inc

HEALTHCARE · MEDICAL DEVICES · USA

Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for cosmetic and reconstructive plastic surgery. The company is headquartered in Alajuela, Costa Rica.

Visit Website →

Want to dig deeper into these stocks?